



FRANK S. WU

Partner

frank.wu@haynesboone.com

PRACTICES: Corporate, Mergers and Acquisitions, Capital Markets and Securities, International, Asia, Investment Management, U.S. Inbound Investment, Corporate Governance, Energy, Power and Natural Resources, Oil and Gas; **INDUSTRIES:** Technology Mergers and Acquisitions

HOUSTON

1221 MCKINNEY STREET
SUITE 4000
HOUSTON, TX 77010
T +1 713.547.2572
F +1 713.236.5659

SHANGHAI

SHANGHAI INTERNATIONAL
FINANCE CENTER
TOWER 2, UNIT 3620,
LEVEL 36, 8 CENTURY
AVENUE, PUDONG
SHANGHAI 200120
T +86.21.6062.6179

EDUCATION AND CLERKSHIPS

- J.D., University of Texas
School of Law, 1996,
Member, *Texas International
Law Journal*
- B.A., Economics, Yale
University, 1993, *cum laude*,
with distinction

ADMISSIONS

- Texas

LANGUAGES

- Chinese (Mandarin)

Frank Wu has helped clients navigate sophisticated transactions from the fields of energy to biotechnology. He has taken start-up companies to successful IPOs and worked with business leaders on strategic alliances, mergers and acquisitions.

Frank co-chairs the Greater China Practice Group representing both U.S. and Chinese companies on domestic and cross-border transactions. In 2008, Frank assisted a Chinese public company in its acquisition of a U.S. target, which was reported by Bloomberg News as one of largest acquisitions of a U.S. target by a Chinese company at the time. Whether the client is a public or private company focused on energy in the oil service sector, biotechnology in licensing and acquisitions, pipeline acquisitions and build-outs, technology growth and IPOs, or chemical distribution internationally, Frank has provided his clients with a wealth of legal experience combined with strategic advice.

Frank works closely with his clients, and has worked with an array of diverse companies but with one similar goal – to work together so that legal needs get balanced with business goals.

Professional Recognition

- Selected for inclusion in *Texas Super Lawyers - Rising Stars Edition*, Thomson Reuters, 2007-2010
- Representation of WuXi Pharmatech in its \$65 million acquisition from NextCode Health named Best US Technology Deal of 2015 by Acquisition International

Professional and Community Activities

- State Bar of Texas
- Houston Bar Association
- American Bar Association
- Yale Alumni Association

Selected Client Representations

- Lead transaction counsel for a major Chinese NYSE-listed biotech company in its US \$160 million acquisition of a U.S. target.

- Lead transaction counsel for a NASDAQ-listed emerging growth company in its initial public offering of US\$36 million in equity and its follow-on public offering of US\$73 million in equity.
- Lead transaction counsel for a NASDAQ-listed company in its US\$920 million merger with an NYSE-listed company in the biotechnology industry.
- Lead transaction counsel to the special committee of a major pipeline company in its US\$70 million acquisition of various pipeline assets.
- Lead transaction counsel to the special committee of a major pipeline company in its US\$200 million exchange of various pipeline assets as part of a US\$1 billion pipeline build-out.
- Lead transaction counsel for a major NYSE-listed biotech company in its \$65 million acquisition of a genomics company.
- Lead transaction counsel for a privately owned Chinese enterprise in its US\$300 million joint venture with a U.S. company in the oil service industry.
- Lead transaction counsel to a foreign company in its acquisition of an oil service company in Singapore.
- Lead transaction counsel to a major international chemical distributor regarding mergers and acquisitions in Latin America.
- Lead transaction counsel to a major international chemical distributor in the negotiation of US\$50 million distribution agreement with a major chemical manufacturer.
- Lead transaction counsel to an energy company regarding the bulk sale of specialty chemicals to various Chinese companies.
- Lead transaction counsel for a group of investors in its \$15 million dollar investment in a biotechnology company.
- Lead transaction counsel to a renewable energy company in its \$15 million EB-5 financing.
- Lead transaction counsel to a biotechnology company in its \$8 million private placement.
- Lead transaction counsel to a U.S. biotech company regarding the licensing of various drug rights in China and the Middle East.
- Counsel to a Chinese oil company in its US\$80 million acquisition of oil participation interests in Ecuador.
- Counsel to an NYSE-listed company in its US\$1.8 billion acquisition of electrical generating assets.
- Counsel to an NYSE-listed company in its US\$900 million acquisition of major pipeline and gas storage assets.
- Counsel to an NYSE-listed utility in its US\$200 million acquisition of various power plants.
- Counsel to a major energy company in its sale of certain gathering facilities, rights of way and other assets located in the Gulf of Mexico.
- Counsel to an international energy company in its US\$125 million project finance lease transaction involving underwater electric transmission cable and in a related equity investment transaction with joint venture partners.
- Counsel to an NYSE-listed company in its US\$72 million acquisition of a paper mill company
- Counsel to a seller in its more than US\$20 million sale of its stevedoring business.

-
- Counsel to a major international oil company in its US\$200 million financing program for gas stations throughout the U.S.
 - Counsel to a NASDAQ-listed issuer in the acquisition of seven information technology services companies and the initial public offering of US\$63.5 million in equity.
 - Counsel to a NASDAQ-listed issuer in the acquisition of eight construction businesses and the initial public offering of US\$103.5 million in equity.
 - Counsel to a major hedge fund in the negotiations with a major utility of a tolling agreement, QSE services agreements and energy management agreements.

Professional Recognition

- Selected for inclusion in *Texas Super Lawyers* - Rising Stars Edition, Thomson Reuters, 2007-2010
- Representation of WuXi Pharmatech in its \$65 million acquisition from NextCode Health named Best US Technology Deal of 2015 by Acquisition International